» Articles » PMID: 25183048

SEOM Clinical Guidelines for the Diagnosis and Treatment of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs) 2014

Overview
Specialty Oncology
Date 2014 Sep 4
PMID 25183048
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

GEP-NENs are a challenging family of tumors of growing incidence and varied clinical management and behavior. Diagnostic techniques have substantially improved over the past decades and significant advances have been achieved in the understanding of the molecular pathways governing tumor initiation and progression. This has already translated into relevant advances in the clinic. This guideline aims to provide practical recommendations for the diagnosis and treatment of GEP-NENs. Diagnostic workup, histological and staging classifications, and the different available therapeutic approaches, including surgery, liver-directed ablative therapies, peptide receptor radionuclide therapy, and systemic hormonal, cytotoxic or targeted therapy, are briefly discussed in this manuscript. Clinical presentation (performance status, comorbidities, tumor-derived symptoms and hormone syndrome in functioning tumors), histological features [tumor differentiation, proliferation rate (Ki-67), and expression of somatostatin receptors], disease localization and extent, and resectability of primary and metastatic disease, are all key issues that shall be taken into consideration to appropriately tailor therapeutic strategies and surveillance of these patients.

Citing Articles

Updates on the Diagnostic Use of Ultrasonography Augmented With Perfluorobutane Contrast in Hepatocellular Carcinoma: A Meta-Analysis.

Wally S, Albalawi Sr A, Al Madshush A, Aljohani M, Alshehri A, Alamrani F Cureus. 2024; 16(5):e60891.

PMID: 38910635 PMC: 11193104. DOI: 10.7759/cureus.60891.


Clinical diagnosis and treatment of 37 cases of gallbladder neuroendocrine carcinoma.

Liu F, Miao W, Nan J, Shi Z, Zhang A, Bo Y World J Surg Oncol. 2024; 22(1):157.

PMID: 38877554 PMC: 11177431. DOI: 10.1186/s12957-024-03436-z.


Assessing the methodological strengths and limitations of the Spanish Society of Medical Oncology (SEOM) guidelines: a critical appraisal using AGREE II and AGREE-REX tool.

Santero M, de Mas J, Rifa B, Clavero I, Rexach I, Bonfill Cosp X Clin Transl Oncol. 2023; 26(1):85-97.

PMID: 37368198 PMC: 10761528. DOI: 10.1007/s12094-023-03219-0.


Diagnostic value of liver contrast-enhanced ultrasound in early hepatocellular carcinoma: a systematic review and meta-analysis.

Zhang Z, Ma C, Luo Y J Gastrointest Oncol. 2023; 14(2):626-635.

PMID: 37201077 PMC: 10186536. DOI: 10.21037/jgo-23-211.


Neuroendocrine Neoplasms of the Gallbladder: A Clinicopathological Analysis of 13 Patients and a Review of the Literature.

Wang P, Chen J, Jiang Y, Jia C, Pang J, Wang S Gastroenterol Res Pract. 2021; 2021:5592525.

PMID: 34122537 PMC: 8166508. DOI: 10.1155/2021/5592525.


References
1.
Akyildiz H, Mitchell J, Milas M, Siperstein A, Berber E . Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery. 2010; 148(6):1288-93. DOI: 10.1016/j.surg.2010.09.014. View

2.
Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder W . TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006; 449(4):395-401. PMC: 1888719. DOI: 10.1007/s00428-006-0250-1. View

3.
Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes J . TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2007; 451(4):757-62. DOI: 10.1007/s00428-007-0452-1. View

4.
Pavel M, Hainsworth J, Baudin E, Peeters M, Horsch D, Winkler R . Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011; 378(9808):2005-2012. DOI: 10.1016/S0140-6736(11)61742-X. View

5.
Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. DOI: 10.1056/NEJMoa1003825. View